Directory

Discover detailed profiles of PoC companies.

CELLWEAVERSE

Innovation in Bio-Pharma Raw Material Supply through Cell Culture Technology

Specialization

Biopharmaceutical Raw Materials
Cell-Based Material Culture Platform
Endotoxin Testing Materials

Keywords

Cellweaverse
C-LAL Test Kit
CMCP
Endotoxin Testing

Cellweaverse develops cell culture-based specialty biologic materials to replace unstable animal-derived biopharmaceutical raw materials.
Its core platform, CMCP, Cell-based Material Culture Platform, enables large-scale culture of specialized animal cells.
The company’s lead product is C-LAL Test Kit, an endotoxin testing material developed using cultured horseshoe crab cell-derived extract.
Cellweaverse aims to solve supply instability, safety risks, and tightening regulations in animal-derived raw material markets.

(1) Owned Technology

(2) Applied Products

C-LAL Test Kit
- Endotoxin testing kit using cultured cell-derived extract.
- Designed as a drop-in replacement for conventional LAL testing.
- Maintains LAL-equivalent mechanism while avoiding horseshoe crab harvesting.
C-Heparin
- Porcine-free heparin alternative pipeline.
- Cell line secured and scalable bioprocess under development.
SINICX
- Magnolia-derived material for skin odor and disease-causing compound degradation.
- Brand Lyseve launched with domestic sales and export activities initiated.
CW-W01
- Vaccine and protein stabilization material pipeline.
- Large-scale manufacturing process under development.

(1) Problem Definition / Development Background

Critical biopharmaceutical raw materials are still heavily dependent on animal harvesting.
LAL test materials are traditionally obtained from horseshoe crab blood, creating supply instability, animal welfare concerns, and regulatory pressure.
Endotoxin testing is essential for vaccines, botulinum toxin, fillers, implantable medical devices, and pharmaceutical QC.
Existing recombinant alternatives have adoption barriers, including higher cost, SOP changes, validation burden, and switching costs.

(2) Value Proposition / Solution

Cellweaverse shifts production from animal harvesting to animal cell culture.
C-LAL preserves the advantages of the LAL test while reducing dependence on horseshoe crab harvesting.
The solution offers low switching cost because existing LAL SOPs can be used.
It enables stable supply, scalable mass production, batch consistency, and stronger ESG positioning.

LAL-Equivalent Mechanism: C-LAL uses the same coagulation reaction mechanism as conventional LAL tests.
Low Switching Barrier: Designed as a drop-in replacement that can use existing LAL SOPs.
Scalable Supply: Uses master cell bank, working cell bank, and cell expansion instead of animal harvesting.
Strong Sensitivity: Sensitivity comparison completed with leading global products from Charles River and Lonza.
Cost Advantage: Target kit price is lower than LAL and rFC alternatives, with reduced production cost.
Regulatory-Friendly Position: Cell-equivalent material may support easier regulatory transition compared with recombinant alternatives.

Established in June 2024.
Secured investment from POSTECH Holdings and Openwater Angels.
Selected for TIPS Program.
Won Grand Prize at Haedong Startup Competition.
Selected for AI Voucher Program and KIT Alternative Testing Commercialization Support Program.
Selected for Global Expansion Network Support Program through Institut Pasteur Korea.
Conducted Global Open Innovation with bioMérieux.
Selected for IBK ChangGong Program and Global PoC Program for Europe.
Third-party validation of C-LAL endotoxin sensitivity completed by KIT in December 2025.

(1) PoC Progress

Cellweaverse has completed PoC in Korea for C-LAL.
EU market entry is in preparation.
Global open innovation activities are underway with bioMérieux.
Discussions are ongoing with Medical and Biological Laboratories in Japan and BNC Korea for domestic and global distribution.

(2) Global Expansion

Initial market entry strategy focuses on Europe through global endotoxin kit manufacturers and distributors.
Target customers include global endotoxin testing kit manufacturers, pharmaceutical QC labs, CDMOs, and medical device companies.
Business model includes B2B raw material supply, B2C test kit supply, licensing, and royalty revenue.
Exit strategy includes possible M&A in 2028 and IPO in 2030 based on pipeline growth.